메뉴 건너뛰기
The Lancet Oncology
Volumn 15, Issue 10, 2014, Pages 1044-1045
Cilengitide in glioblastoma: When did it fail?
Author keywords

[No Author keywords available]
Indexed keywords

CILENGITIDE; TEMOZOLOMIDE; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SNAKE VENOM; TUMOR SUPPRESSOR PROTEIN;
EID: 84908567202     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70403-6     Document Type: Note
Times cited : (34)
References (10)
  • 1
    • 84908563697 scopus 로고    scopus 로고
    • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
    • for the European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortiumthe Canadian Brain Tumor Consortium, the CENTRIC study teamthe CENTRIC study team, published online Aug 20.
    • Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014, for the European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortiumthe Canadian Brain Tumor Consortium, the CENTRIC study teamthe CENTRIC study team, published online Aug 20. http://dx.doi.org/10.1016/S1470-2045(14)70379-1.
    • (2014) Lancet Oncol
    • Stupp, R.1    Hegi, M.E.2    Gorlia, T.3
  • 2
    • 64149106522 scopus 로고    scopus 로고
    • Stimulation of tumour growth and angiogenesis by low concentrations of RGD-mimetic integrininhibitors
    • Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumour growth and angiogenesis by low concentrations of RGD-mimetic integrininhibitors. Nat Med 2009, 15:392-400.
    • (2009) Nat Med , vol.15 , pp. 392-400
    • Reynolds, A.R.1    Hart, I.R.2    Watson, A.R.3
  • 3
    • 34548175694 scopus 로고    scopus 로고
    • 5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
    • 5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007, 18:1400-1407.
    • (2007) Ann Oncol , vol.18 , pp. 1400-1407
    • Hariharan, S.1    Gustafson, D.2    Holden, S.3
  • 4
    • 73249136703 scopus 로고    scopus 로고
    • Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
    • Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009, 11:747-756.
    • (2009) Neuro Oncol , vol.11 , pp. 747-756
    • Maurer, G.D.1    Tritschler, I.2    Adams, B.3
  • 5
    • 64249086909 scopus 로고    scopus 로고
    • Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
    • Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009, 124:2719-2727.
    • (2009) Int J Cancer , vol.124 , pp. 2719-2727
    • Mikkelsen, T.1    Brodie, C.2    Finniss, S.3
  • 6
    • 84899886083 scopus 로고    scopus 로고
    • Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression
    • Eisele G, Wick A, Eisele AC, et al. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol 2014, 117:141-145.
    • (2014) J Neurooncol , vol.117 , pp. 141-145
    • Eisele, G.1    Wick, A.2    Eisele, A.C.3
  • 7
    • 57149108506 scopus 로고    scopus 로고
    • Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
    • Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26:5610-5617.
    • (2008) J Clin Oncol , vol.26 , pp. 5610-5617
    • Reardon, D.A.1    Fink, K.L.2    Mikkelsen, T.3
  • 8
    • 77954924659 scopus 로고    scopus 로고
    • Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
    • Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28:2712-2718.
    • (2010) J Clin Oncol , vol.28 , pp. 2712-2718
    • Stupp, R.1    Hegi, M.E.2    Neyns, B.3
  • 9
    • 84868193304 scopus 로고    scopus 로고
    • A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
    • Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012, 118:5601-5607.
    • (2012) Cancer , vol.118 , pp. 5601-5607
    • Nabors, L.B.1    Mikkelsen, T.2    Hegi, M.E.3
  • 10
    • 84894194756 scopus 로고    scopus 로고
    • Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
    • Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014, 370:709-722.
    • (2014) N Engl J Med , vol.370 , pp. 709-722
    • Chinot, O.L.1    Wick, W.2    Mason, W.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.